RecruitingPhase 1NCT05765851

A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors

A Phase 1, 2-Part, Multicenter, First-In-Human Dose-Escalation and Dose-Expansion Study of DS-1103a Combination Therapy in Subjects With Advanced Solid Tumors

Sponsor

Daiichi Sankyo

Enrollment

108 participants

Start Date

May 30, 2023

Study Type

INTERVENTIONAL

Conditions

Advanced Solid Tumor

Summary

This study will evaluate the safety and efficacy of DS-1103a combination therapy in participants with advanced solid tumors.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called DS-1103a and a drug called T-DXd for people with advanced solid tumor. The study is currently recruiting participants at 8 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDS-1103a

One IV infusion Q3W on Day 1 of each 21-day cycle

DRUGT-DXd

One IV infusion Q3W on Day 1 of each 21-day cycle

Locations(8)

Florida Cancer Specialists

Sarasota, Florida, United States

Lifespan Cancer Institute

Providence, Rhode Island, United States

University of Utah

Salt Lake City, Utah, United States

NEXT Oncology

Fairfax, Virginia, United States

Princess Margaret Cancer Centre, University Health Network

Toronto, Canada

Oncopole - Institut Claudius Regaud

Toulouse, Haute Garonne, France

Centre Léon Bérard

Lyon, Rhone, France

Hospital Universitari Vall d'Hebron

Barcelona, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05765851

Related Trials

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies

NCT0721383011 locations

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

NCT0526762618 locations

A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours

NCT0683300813 locations

A Study of LM-168 Combined With Other Anti-tumor Treatments in Participants With Advanced Solid Tumors

NCT076694151 location

A Study of IDP-001 in Advanced or Metastatic Solid Tumors

NCT076028424 locations